Cellectar Biosciences
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLRB and other ETFs, options, and stocks.About CLRB
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination.
CEOJames V. Caruso
CEOJames V. Caruso
Employees11
Employees11
HeadquartersFlorham Park, New Jersey
HeadquartersFlorham Park, New Jersey
Founded1996
Founded1996
Employees11
Employees11
CLRB Key Statistics
Market cap13.33M
Market cap13.33M
Price-Earnings ratio-0.22
Price-Earnings ratio-0.22
Dividend yield—
Dividend yield—
Average volume112.62K
Average volume112.62K
High today$5.20
High today$5.20
Low today$4.89
Low today$4.89
Open price$4.98
Open price$4.98
Volume52.84K
Volume52.84K
52 Week high$94.50
52 Week high$94.50
52 Week low$4.36
52 Week low$4.36
People also own
Based on the portfolios of people who own CLRB. This list is generated using Robinhood data, and it’s not a recommendation.